+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sickle Cell Disease - Pipeline Review, H2 2019

  • ID: 4901321
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 278 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Epidestiny Inc
  • Glycan Therapeutics Inc
  • MimeTech Srl
  • Phoenicia Biosciences Inc
  • MORE
Sickle Cell Disease - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H2 2019, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 10, 13, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 1 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Agios Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Epidestiny Inc
  • Glycan Therapeutics Inc
  • MimeTech Srl
  • Phoenicia Biosciences Inc
  • MORE
Introduction
Report Coverage
Sickle Cell Disease - Overview
Sickle Cell Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sickle Cell Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sickle Cell Disease - Companies Involved in Therapeutics Development
Agios Pharmaceuticals Inc
Alkermes Plc
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
ArQule Inc
Aruvant Sciences Inc
Axcella Health Inc
Beam Therapeutics Inc
bluebird bio Inc
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Cannabis Science Inc
Cell Source Inc
CRISPR Therapeutics AG
CSL Ltd
Cyclerion Therapeutics Inc
Dystrogen Therapeutics SA
Ebelle Pharmaceuticals Inc
Editas Medicine Inc
Emmaus Life Sciences Inc
Epidestiny Inc
Epizyme Inc
Errant Gene Therapeutics LLC
ExCellThera Inc
Forma Therapeutics Inc
Fulcrum Therapeutics Inc
Functional Fluidics LLC
Gamida Cell Ltd
Gilead Sciences Inc
Global Blood Therapeutics Inc
Glycan Therapeutics Inc
Hillhurst Biopharmaceuticals Inc
Homology Medicines Inc
Imara Inc
Intellia Therapeutics Inc
Invenux LLC
La Jolla Pharmaceutical Company
MaxCyte Inc
Merck & Co Inc
Micelle BioPharma Inc
MimeTech Srl
Modus Therapeutics AB
Molecules For Health Inc
Morphogenesis Inc
Novartis AG
Oryzon Genomics SA
Pfizer Inc
PHD Biosciences
Phoenicia Biosciences Inc
Protagonist Therapeutics Inc
Rare Partners Srl
Regenacy Pharmaceuticals LLC
ReNeuroGen LLC
Sangamo Therapeutics Inc
Secura Bio Inc
Syros Pharmaceuticals Inc
Trucode Gene Repair Inc
Vanguard Therapeutics Inc
Sickle Cell Disease - Drug Profiles
Sickle Cell Disease - Dormant Projects
Sickle Cell Disease - Discontinued Products
Sickle Cell Disease - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Sickle Cell Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Sickle Cell Disease - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Sickle Cell Disease - Pipeline by Alkermes Plc, H2 2019
Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H2 2019
Sickle Cell Disease - Dormant Projects, H2 2019
Sickle Cell Disease - Dormant Projects, H2 2019 (Contd..1), H2 2019
Sickle Cell Disease - Dormant Projects, H2 2019 (Contd..2), H2 2019
Sickle Cell Disease - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Sickle Cell Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Agios Pharmaceuticals Inc
  • Alkermes Plc
  • Angiocrine Bioscience Inc
  • Annexin Pharmaceuticals AB
  • ArQule Inc
  • Aruvant Sciences Inc
  • Axcella Health Inc
  • Beam Therapeutics Inc
  • bluebird bio Inc
  • Bristol-Myers Squibb Co
  • C4X Discovery Holdings Plc
  • Cannabis Science Inc
  • Cell Source Inc
  • CRISPR Therapeutics AG
  • CSL Ltd
  • Cyclerion Therapeutics Inc
  • Dystrogen Therapeutics SA
  • Ebelle Pharmaceuticals Inc
  • Editas Medicine Inc
  • Emmaus Life Sciences Inc
  • Epidestiny Inc
  • Epizyme Inc
  • Errant Gene Therapeutics LLC
  • ExCellThera Inc
  • Forma Therapeutics Inc
  • Fulcrum Therapeutics Inc
  • Functional Fluidics LLC
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • Global Blood Therapeutics Inc
  • Glycan Therapeutics Inc
  • Hillhurst Biopharmaceuticals Inc
  • Homology Medicines Inc
  • Imara Inc
  • Intellia Therapeutics Inc
  • Invenux LLC
  • La Jolla Pharmaceutical Company
  • MaxCyte Inc
  • Merck & Co Inc
  • Micelle BioPharma Inc
  • MimeTech Srl
  • Modus Therapeutics AB
  • Molecules For Health Inc
  • Morphogenesis Inc
  • Novartis AG
  • Oryzon Genomics SA
  • Pfizer Inc
  • PHD Biosciences
  • Phoenicia Biosciences Inc
  • Protagonist Therapeutics Inc
  • Rare Partners Srl
  • Regenacy Pharmaceuticals LLC
  • ReNeuroGen LLC
  • Sangamo Therapeutics Inc
  • Secura Bio Inc
  • Syros Pharmaceuticals Inc
  • Trucode Gene Repair Inc
  • Vanguard Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll